+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Overactive Bladder Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5176043
  • Report
  • August 2020
  • Region: Global
  • 111 Pages
  • Mordor Intelligence


  • Allergan PLC
  • Astellas Pharma Inc.
  • Cogentix Medical Inc.
  • Endo International PLC
  • Johnson & Johnson
  • Machloed pharmaceuticals
The overactive bladder (OAB) treatment market is expected to register a CAGR of 3.4% over the forecast period. The increasing incidence of diseases, such as Parkinson’s disease, which leads to overactive bladder disorder, and rising geriatric population, are primary drivers of the global market. In 2017, as per the World Ageing Report, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Urinary incontinence generally increases with aging. OAB has a major negative impact on the quality of life and health of the aged population. With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.

Key Market Trends

Idiopathic Overactive Bladder Treatment Segment is Expected to Hold a Major Share in the Overactive Bladder Treatment Market

Idiopathic overactive bladder treatment is expected to majorly contribute to the revenues over the forecast period, owing to its high prevalence. Due to the bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to the condition. In 2017, as per the National Association for Incontinence, the urinary incontinence affected about 200 million people worldwide. This is expected to encourage key companies to invest in this segment. Increasing competition among the market players may lead to a decrease in the overall cost of treatment, during the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to lead the overactive bladder treatment market. This can be credited to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the growing prevalence of the disease with rising age, and the presence of major players, the market is expected to grow during the forecast period. According to the National Association for Incontinence 2020, approximately 25 million adult Americans suffer from some form of urinary incontinence, among them 75-80% are women. Due to the increasing prevalence of bladder over-activity, geriatric population, healthcare expenditure, and awareness about overactive bladder treatments, the Asia-Pacific region is expected to register the highest CAGR during the forecast period.

Competitive Landscape

The overactive bladder treatment market is moderately fragmented, with global pharmaceutical companies controlling significant market share. Moreover, the generic space of the market is observing a trend of consolidation and high competition. Major market players include Allergan PLC, Astellas Pharma Inc., Cogentix Medical Inc., Endo International PLC, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson, Medtronic PLC, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Limited, and Macleods Pharmaceuticals Ltd, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • Allergan PLC
  • Astellas Pharma Inc.
  • Cogentix Medical Inc.
  • Endo International PLC
  • Johnson & Johnson
  • Machloed pharmaceuticals

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Aging Population and Increasing Prevalence of Diseases Causing Overactive Bladder
4.2.2 Increasing Trend of Drug Development for Overactive Bladder Treatment
4.3 Market Restraints
4.3.1 Side Effects of Current Treatments
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Therapy
5.1.1 Anticholinergics
5.1.2 Mirabegron
5.1.3 Neurostimulation
5.1.4 Intravesical Instillation
5.1.5 Other Therapies
5.2 By Disease Type
5.2.1 Idiopathic Overactive Bladder
5.2.2 Neurogenic Overactive Bladder
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Allergan PLC
6.1.2 Astellas Pharma Inc.
6.1.3 Cogentix Medical Inc.
6.1.4 Endo International PLC
6.1.5 Hisamitsu Pharmaceutical Co. Inc.
6.1.6 Johnson & Johnson
6.1.7 Medtronic PLC
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Teva Pharmaceutical Industries Limited
6.1.11 Machloed pharmaceuticals
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Allergan PLC
  • Astellas Pharma Inc.
  • Cogentix Medical Inc.
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co. Inc.
  • Johnson & Johnson
  • Medtronic PLC
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Machloed pharmaceuticals
Note: Product cover images may vary from those shown